Pharmacokinetics, druglikeness and anti-asthmatic potential of 6-dehydrogingerdione via modulation of β2-adrenergic receptor

C. Lalrinmawia, C. Biakthansanga, Ricky Lalruatfela, B. Lalruatfela

Science Vision 23 (2), 29-34 | Published on 8 August 2023 | https://doi.org/10.33493/scivis.23.02.02

Abstract

Asthma is a common chronic disease infecting the lower airway resulting in cough, chest constriction and wheezing. Treatment of asthma includes drugs such as salbutamol, levalbuterol, metaproterenol and terbutaline as these can cause relaxation of the muscles of the windpipe. One of the most common spices that is enriched with numerous medicinal properties is ginger, which is reported to have anti-inflammatory, antidiabetic, antiemetic, anticancer and anti-obesity properties. In this paper we analyse the pharmacokinetics, druglikeness and binding affinity of 6-dehydrogingerdione (6-DG) to β2-adrenergic receptor (ADRB2) using in silico approach. We observe that 6-DG fulfilled druglikeness tests and may be safe for human consumption and also exhibited a strong binding affinity to ADRB2 which is comparable to the standard asthma drug salbutamol. The amino acids involved in the interaction of 6-DG and salbutamol to ADRB2 differ only by one residue. We concluded that further in vitro and in vivo analyses are required to confirm the potential of 6-DG as an anti-asthmatic medication.

Abstract Full Text Download